XLO logo

Xilio Therapeutics (XLO) Company Overview

Profile

Full Name:

Xilio Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

October 22, 2021

Indexes:

Not included

Description:

Xilio Therapeutics is a biotechnology company focused on developing innovative cancer treatments. They create therapies that target tumors while minimizing damage to healthy cells. Their goal is to improve patient outcomes and quality of life through advanced, precise cancer care solutions.

Events Calendar

Earnings

Next earnings date:

Apr 1, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Apr 1, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Nov 8, 24 Raymond James
Outperform
May 30, 23 Chardan Capital
Buy
May 11, 23 Chardan Capital
Buy
Jan 27, 23 Morgan Stanley
Overweight
Dec 21, 22 Chardan Capital
Buy
Nov 10, 22 Raymond James
Outperform
Aug 10, 22 Morgan Stanley
Overweight
Jan 10, 22 HC Wainwright & Co.
Buy
Nov 16, 21 Raymond James
Outperform
Nov 16, 21 Morgan Stanley
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Xilio Therapeutics?
  • Does Xilio Therapeutics pay dividends?
  • What sector is Xilio Therapeutics in?
  • What industry is Xilio Therapeutics in?
  • What country is Xilio Therapeutics based in?
  • When did Xilio Therapeutics go public?
  • Is Xilio Therapeutics in the S&P 500?
  • Is Xilio Therapeutics in the NASDAQ 100?
  • Is Xilio Therapeutics in the Dow Jones?
  • When was Xilio Therapeutics's last earnings report?
  • When does Xilio Therapeutics report earnings?
  • Should I buy Xilio Therapeutics stock now?

What is the ticker symbol for Xilio Therapeutics?

The ticker symbol for Xilio Therapeutics is NASDAQ:XLO

Does Xilio Therapeutics pay dividends?

No, Xilio Therapeutics does not pay dividends

What sector is Xilio Therapeutics in?

Xilio Therapeutics is in the Healthcare sector

What industry is Xilio Therapeutics in?

Xilio Therapeutics is in the Biotechnology industry

What country is Xilio Therapeutics based in?

Xilio Therapeutics is headquartered in United States

When did Xilio Therapeutics go public?

Xilio Therapeutics's initial public offering (IPO) was on October 22, 2021

Is Xilio Therapeutics in the S&P 500?

No, Xilio Therapeutics is not included in the S&P 500 index

Is Xilio Therapeutics in the NASDAQ 100?

No, Xilio Therapeutics is not included in the NASDAQ 100 index

Is Xilio Therapeutics in the Dow Jones?

No, Xilio Therapeutics is not included in the Dow Jones index

When was Xilio Therapeutics's last earnings report?

Xilio Therapeutics's most recent earnings report was on Nov 7, 2024

When does Xilio Therapeutics report earnings?

The next expected earnings date for Xilio Therapeutics is Apr 1, 2025

Should I buy Xilio Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions